Capricor Therapeutics (LTS:0HTB) Cyclically Adjusted Book per Share: €0.00 (As of Mar. 2026)


What is Capricor Therapeutics Cyclically Adjusted Book per Share?

Capricor Therapeutics LTS:0HTB 37 Cyclically Adjusted Book per Share is €0.00 as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Capricor Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €57.812. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Capricor Therapeutics's average Cyclically Adjusted Book Growth Rate was 31.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Capricor Therapeutics was 12.30% per year. The lowest was -58.90% per year. And the median was -2.80% per year.

As of today (2026-07-07), Capricor Therapeutics's current stock price is €0.00. Capricor Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €0.00. Capricor Therapeutics's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Capricor Therapeutics was 37.92. The lowest was 0.10. And the median was 1.25.


Capricor Therapeutics  (LTS:0HTB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Capricor Therapeutics was 37.92. The lowest was 0.10. And the median was 1.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Capricor Therapeutics Cyclically Adjusted Book per Share Related Terms


Capricor Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Cyclically Adjusted Book per Share Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTB vs COAG, DMRA, MPLT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted PB Ratio falls into.



Capricor Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Capricor Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=57.812/330.2130*330.2130
=57.812

Current CPI (Mar. 2026) = 330.2130.

Capricor Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -2.529 241.018 -3.465
201609 0.021 241.428 0.029
201612 -1.773 241.432 -2.425
201703 -3.143 243.801 -4.257
201706 -2.594 244.955 -3.497
201709 -1.427 246.819 -1.909
201712 3.607 246.524 4.831
201803 3.084 249.554 4.081
201806 2.748 251.989 3.601
201809 1.949 252.439 2.549
201812 1.292 251.233 1.698
201903 0.982 254.202 1.276
201906 0.603 256.143 0.777
201909 0.777 256.759 0.999
201912 1.476 256.974 1.897
202003 2.082 258.115 2.664
202006 6.741 257.797 8.635
202009 6.191 260.280 7.854
202012 5.559 260.474 7.047
202103 7.329 264.877 9.137
202106 6.644 271.696 8.075
202109 7.488 274.310 9.014
202112 6.657 278.802 7.885
202203 5.366 287.504 6.163
202206 4.249 296.311 4.735
202209 3.736 296.808 4.156
202212 2.668 296.797 2.968
202303 1.390 301.836 1.521
202306 0.605 305.109 0.655
202309 -0.402 307.789 -0.431
202312 4.970 306.746 5.350
202403 4.067 312.332 4.300
202406 2.562 314.175 2.693
202409 14.750 315.301 15.448
202412 33.313 315.605 34.855
202503 28.315 319.799 29.237
202506 21.826 322.561 22.344
202509 17.135 324.800 17.421
202512 62.625 324.054 63.815
202603 57.812 330.213 57.812

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €0.00 mean?
Capricor Therapeutics (LTS:0HTB) has a Cyclically Adjusted Book per Share of €0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors.
Is Capricor Therapeutics' Cyclically Adjusted Book per Share too high?
Capricor Therapeutics' current Cyclically Adjusted Book per Share is €0.00. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' Cyclically Adjusted Book per Share compare to COAG and DMRA?
Capricor Therapeutics' Cyclically Adjusted Book per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Capricor Therapeutics and its competitors. Capricor Therapeutics's current Cyclically Adjusted Book per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (LTS:0HTB) has a current Cyclically Adjusted Book per Share of €0.00. The current Cyclically Adjusted Book per Share is €0.00. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current Cyclically Adjusted Book per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.